Insulet (NSDQ:PODD) touted data today from the 1st feasibility study of its Omnipod Horizon hybrid closed-loop system in patients with Type 1 diabetes. Data from the study showed that the Omnipod automated glucose control algorithm performed well, with minimal hypoglycemia, and that it was safe.
The Billerica, Mass.-based company enrolled 24 patients with Type 1 diabetes in the 36-hour study. The feasibility trial used a modified version of Insulet’s Omnipod, a Dexcom continuous glucose monitor and Insulet’s personalized model predictive control algorithm.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet touts Omnipod Horizon hybrid closed-loop system in patients with T1D appeared first on MassDevice.
from MassDevice http://ift.tt/2m2XhVT
Cap comentari:
Publica un comentari a l'entrada